GlassScriptPhysician profile
Albis Acosta
NPI 1407842073
$2,346.11
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2021: $123.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,555.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2019 | |
| Eisai INC. | $122.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $119.41 | 2019 | |
| Biogen, INC. | $106.83 | 2021 | |
| Greenwich Biosciences, INC. | $96.16 | 2019 | |
| Mdd US Operations, LLC | $89.31 | 2019 | |
| Lilly USA, LLC | $80.30 | 2019 | |
| Genzyme Corporation | $35.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albis Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.